rrx-001,AdAPT-001
epicentrx
['rrx-001 ', 'epicentrx']
today is the first day of the 2023 annual meeting. our team is excited to provide clinical updates on our two lead treatment candidates, rrx-001 and adapt-001 at #asco23 in chicago. learn more here: 
Innovation-driven drug and device company with a focus on minimally toxic therapies for cancer and chronic diseases. #cancertherapy #biotech